UGT2B17 Genetic Polymorphisms Dramatically Affect the Pharmacokinetics of MK-7246 in Healthy Subjects in a First-in-Human Study

MK-7246, an antagonist of the chemoattractant receptor on T helper type 2 (Th2) cells, is being developed for the treatment of respiratory diseases. In a first-in-human study, we investigated whether genetic polymorphisms contributed to the marked intersubject variability in the pharmacokinetics of...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Y-H, Trucksis, M, McElwee, J J, Wong, P H, Maciolek, C, Thompson, C D, Prueksaritanont, T, Garrett, G C, Declercq, R, Vets, E, Willson, K J, Smith, R C, Klappenbach, J A, Opiteck, G J, Tsou, J A, Gibson, C, Laethem, T, Panorchan, P, Iwamoto, M, Shaw, P M, Wagner, J A, Harrelson, J C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3380185/
https://www.ncbi.nlm.nih.gov/pubmed/22669291
http://dx.doi.org/10.1038/clpt.2012.20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3380185/
https://www.ncbi.nlm.nih.gov/pubmed/22669291
http://dx.doi.org/10.1038/clpt.2012.20

Ejemplares similares